AAV capsid

Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer

Pfizer has transferred an AAV capsid designed for a rare neurological disease target to AstraZeneca’s rare disease subsidiary, Alexion, as ...